Led · Series A · Jul 2026

Yuanli Semiconductor (原粒半导体（881121）), founded in April 2023, focuses on end-side AI inference and architecture design for the Agent Computer paradigm. It positions its products as "edge productivity AI chips" intended to bring server-class intelligence to desktop and edge devices for local, high-performance, energy-efficient, and controllable compute. The company has developed a technology stack composed of CalcuMex, CalcuGrid and CalcuKit to address model inference efficiency, AI chiplet interconnect, and multi-chip scheduling. Yuanli has completed its first chip engineering verification and begun product validation and deployment of productivity-grade edge compute products. Target deployment scenarios include enterprise office, industry agent applications, and industrial intelligence, and the company plans to continue building its software-hardware ecosystem to scale applications.

Participated · Series A · Nov 2025

Infinigence AI develops full-stack, AI-native infrastructure technologies and products focused on the requirements of large models and AGI-related workloads. The company was founded in May 2023 and is led by co-founder and CEO Xia Lixue, with co-founders including Tsinghua professor Wang Yu and Chief Scientist Dai Guohao. It is positioned as a multi-heterogeneous technology provider aiming to expand large-scale computing power for the Token economy and to build infrastructure with autonomous evolution capabilities. The company has raised over CNY2.2 billion to date, including the latest raise of more than CNY700 million. Management says the new funds will be used to consolidate its technology stack, scale compute capacity, accelerate productivity shifts, and deliver infrastructure solutions across industry scenarios. The company is described in reporting as a leading AI-native infrastructure firm in China by cumulative funding.

Participated · Series A · Dec 2023

Xingsai Bio develops single-cell analysis instruments and supporting reagents and consumables. It offers an integrated “single-cell Raman imaging – sorting – sequencing – culture” solution. The company’s products and workflows target clinical precision medicine, human and environmental microbiomes, bioresource mining, cell-factory screening, industrial process monitoring, and biosafety. A recent corporate registration change shows a new shareholder entry for Maotai Sci‑Tech Innovation Fund holding 2.2222% of shares. The article does not disclose revenue, user metrics, or other financial details. Xingsai Biotech is a developer of single-cell analysis instruments and accompanying reagents and consumables. The company provides an integrated “single-cell Raman imaging–sorting–sequencing–culture” solution. Its platform is positioned to serve clinical precision medicine, human and environmental microbiome research, bioprospecting, cell-factory screening, industrial process monitoring, and biosafety. Recently the company completed a nearly ¥100 million Series A financing. Proceeds from the round will support expansion of the company’s industrial layout and accelerate R&D on its “Raman Group” industrial project and microfluidic technologies. The company also plans to strengthen brand building and to open international markets.